Replies to post #48184 on NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

"GSK has nothing to do with NWBO or DCVax."

You posted a quote from MD Anderson that says that Budzar had no conflict of interest with DCVax-Direct. I responded that they absolutely did have a conflict of interest due to a huge contract with GSK for a competing therapy. Note that the dates below are not ancient history. This was all happening about the same time that you and Budzar were maligning DCVax-Direct.

Here is a little bit more about GSK's aggressive and illegal practices in competition:

Business News | Fri Sep 19, 2014 9:45am EDT
http://www.reuters.com/article/us-gsk-china-idUSKBN0HE0TC20140919

"China fined GlaxoSmithKline Plc (GSK.L) a record 3 billion yuan ($489 million) on Friday for paying bribes to doctors to use its drugs,"
--------------------------------------------------------------------

The super lucrative collaboration between MDA and GSK was in the immunotherapy realm:

http://www.mdanderson.org/newsroom/news-releases/2014/collaboration-with-gsk.html

"MD Anderson News Release 04/08/14

The University of Texas MD Anderson Cancer Center announced today it formed a research alliance with GlaxoSmithKline (GSK), a global leader in pharmaceutical development, to strengthen its efforts in advancing therapies that train the body’s immune system to combat cancer.

The collaboration completes an ambitious plan to partner with leading pharmaceutical companies to more rapidly develop cancer immunotherapies as part of MD Anderson’s Moon Shots Program. Through this venture, GSK and MD Anderson will work together to identify new therapeutic approaches, evaluate patient responses in clinical trials and use those insights to develop immunotherapy drugs."
--------------------------------------------------------------------------

http://www.bioworld.com/content/md-anderson-gsk-ink-potential-335m-oncology-drug-pact-0

"Houston-based MD Anderson granted GSK exclusive worldwide rights to develop and commercialize the antibodies, which activate OX40 on the surface of T cells, in a deal potentially valued at more than $335 million. London-based GSK will make an undisclosed up-front license payment, fund research collaboration activities at MD Anderson's Institute for Applied Cancer Science (IACS) and provide payments for reaching development, regulatory and commercial milestones. MD Anderson also will be entitled to royalties from the commercial sales of products developed under the collaboration."